First-Line Pharmacologic Options for Alcohol Use Disorder
For adults with alcohol use disorder and normal liver function, use oral naltrexone (50 mg/day) or acamprosate (1,998 mg/day for ≥60 kg) as first-line agents, both combined with psychosocial interventions; however, in patients with alcoholic liver disease or cirrhosis, acamprosate is preferred due to its renal-only excretion and lack of hepatotoxicity, while baclofen (30-60 mg/day) is the only medication with proven safety and efficacy specifically in cirrhotic patients. 1, 2, 3, 4
Selection Algorithm Based on Organ Function
Patients WITHOUT Liver Disease
Oral naltrexone 50 mg/day is a first-line option with:
- Number needed to treat (NNT) of 18 to prevent return to any drinking 4
- NNT of 11 to prevent return to heavy drinking 4
- Critical contraindication: Do NOT use in patients with elevated liver enzymes or any evidence of alcoholic liver disease due to hepatotoxicity risk 2, 5
- Expect gastrointestinal side effects (nausea risk ratio 1.73, vomiting risk ratio 1.53 compared to placebo) 4
Acamprosate 1,998 mg/day (666 mg three times daily) is equally first-line with:
- NNT of 11-12 to prevent return to any drinking 4, 6
- Major advantage: No hepatic metabolism, renally excreted only 2, 3
- Dose adjustment: Reduce by one-third for body weight <60 kg 5
- Start 3-7 days after last alcohol consumption once withdrawal symptoms resolve 5
- Expect diarrhea (risk ratio 1.58 vs placebo) 4
- Contraindication: Severe renal impairment (creatinine clearance <30 mL/min) 3
Patients WITH Alcoholic Liver Disease or Cirrhosis
Acamprosate remains safe in liver disease:
- No reported hepatotoxicity in any trials 2, 3, 6
- However, has NOT been formally tested in cirrhotic patients in randomized trials 2
- Monitor renal function closely as this is the sole excretion route 3
Baclofen 30-60 mg/day is the ONLY medication with proven efficacy specifically in cirrhosis:
- Single randomized controlled trial demonstrated safety and efficacy in both compensated and decompensated cirrhotic patients 1, 3
- GABA-B receptor agonist with minimal hepatic metabolism 3
- Can be used for both alcohol withdrawal syndrome AND long-term relapse prevention 2
- Critical monitoring: Watch for worsening mental status/sedation and renal dysfunction 3
- Considered first-line pharmacotherapy for AUD in patients with ALD 7, 8
Explicitly AVOID in liver disease:
- Naltrexone: Not tested in cirrhosis, causes hepatocellular injury, NOT recommended 2, 5
- Disulfiram: Potential hepatotoxicity, should be avoided in severe ALD 2, 5
Patients WITH Renal Impairment
Avoid acamprosate if creatinine clearance <30 mL/min (renally excreted) 3
Consider baclofen or naltrexone (if no liver disease):
- Baclofen requires dose adjustment in renal failure 3
- Naltrexone has mostly renal excretion but can be used with monitoring 3
Gabapentin (600-1,800 mg/day) is an alternative:
Adherence Considerations
For poor adherence or supervised settings:
- Injectable naltrexone 380 mg monthly reduces drinking days by approximately 5 days per 30-day period compared to placebo 3, 4
- Eliminates daily pill burden 2
For optimal adherence:
- All oral medications require combination with psychosocial interventions (cognitive behavioral therapy, motivational enhancement therapy) 1, 3, 9
- Treatment duration typically 3-6 months, can extend to 12 months 5
Common Pitfalls to Avoid
Never use naltrexone in patients with ANY evidence of liver disease - this is explicitly contraindicated despite its efficacy in general AUD populations 2, 5
Do not start acamprosate during active drinking - it maintains rather than induces remission and should begin after withdrawal symptoms resolve 1
Do not forget thiamine supplementation (100-300 mg/day) in all patients with AUD to prevent Wernicke encephalopathy 5
Abstinence is non-negotiable - continued alcohol use in liver disease patients dramatically worsens outcomes and progression to cirrhosis 1